Роль легочной гиперинфляции в патогенезе хронической обструктивной болезни легких. Роль поддерживающей терапии в уменьшении легочной гиперинфляции

1. Global Initiative for Chronic Obstructive Lung Diseases (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO workshop report. Publication Number 2701, April 2001: 1-100. Updated 2003. GOLD website (www.goldcopd.com).

2. ZuWallack R. Clinical interpretation of health-related quality of life outcomes in chronic obstructive pulmonary disease. Eur. Respir. Rev. 2002; 12 (83): 65-66.

3. O'Donnell D.E. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful? Chest 2000; 117: 42S-47S.

4. Wolkove N., Dajczman E., Colacone A. et al. The relationship between pulmonary function and dyspnea in obstructive lung disease. Chest 1989; 96: 1247-1251.

5. Hay J.G., Stone P., Carter J. et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur. Respir. J. 1992; 5: 659-664.

6. Shoup R., Dalsky G., Warner S. et al. Body composition and health-related quality of life in patients with obstructive airways disease. Eur. Respir. J. 1997; 10: 1576-1580.

7. Belman M.J., Botnick W.C., Shin J.W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153: 967-975.

8. O'Donnell D.E., Lam M., Webb K.A. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542-549.

9. Черняк А.В., Авдеев C.H., Пашкова Т.Л., Айсанов З.Р. Бронходилатационный тест у больных с хронической обструктивной болезнью легких. Пульмонология 2003; 1: 50-56.

10. Macklem Р.Т. Hyperinflation. Am. Rev. Respir. Dis. 1984; 129: 1-2.

11. Milic-Emili J. Dynamic pulmonary hyperinflation and intrinsic PEEP: consequences and management in patients with chronic obstructive pulmonary disease. Rec. Progr. Med. 1990; 81: 733-737.

12. Similowski T., Derenne J.-P., Milic-Emili J. Respiratory mechanics during acute respiratory failure of chronic obstructive pulmonary disease. Bronchodilators and corticosteroids. In: Derenne J.-P., Whitelaw W.A., Similowski T., eds. Acute respiratory failure in chronic obstructive pulmonary disease. New York: Marcel Dekker; Inc., 1995. 23-46.

13. Авдеев C.H., Чучалин А.Г. Дыхательная недостаточность при хронической обструктивной болезни легких. В кн.: Чучалин А.Г. (ред.) Хронические обструктивные болезни легких. М.: ЗАО Изд-во "БИНОМ"; СПб.: Невский диалект; 1998. 249-275.

14. De Troyer A. Effect of hyperinflation on the diaphragm. Eur. Respir. J. 1997; 10: 708-712.

15. Similowski T., Yan S., Gauthier A.P. et al. Contractile properties of the human diaphragm during chronic hyperinflation. N. Engl. J. Med. 1991; 325: 917-923.

16. Whitelaw W.A., Hajdo L.E., Wallace J.A. Relationships among pressure, tension, and shape of the diaphragm. J. Appl. Physiol. 1983; 62: 180-186.

17. Cassart Af., Pettiaux N., Gevenois P.A. et al. Effect of chronic hyperinflation on diaphragm length and surface area. Am. J. Respir. Crit. Care Med. 1997; 156: 504-508.

18. Decramer M. Hyperinflation and respiratory muscle interaction. Eur. Respir. J. 1997; 10: 934-941.

19. O'Donnell D.E., Webb K.A. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am. Rev. Respir. Dis. 1993; 148: 1351-1357.

20. O'Donnell D.E., Bertley J.C., Chau L.L. et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am. J. Respir. Crit. Care Med. 1997; 155: 109-115.

21. Diaz O.. Villajranca C., Ghezzo H. et al. Breathing pattern and gas exchange at peak exercise in COPD patients with and without tidal flow limitation at rest. Eur. Respir. J. 2001; 17: 1120-1127.

22. O'Donnell D.E., D'Arsigny C., Fitzpatrick M., Webb K.A. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am. J. Respir. Crit. Care Med. 2002; 166: 663-668.

23. Brochard L. Intrinsic (or auto-) PEEP during controlled mechanical ventilation. Intensive Care Med. 2002; 28: 1376-1378.

24. Haluszka J., Chartrand D.A., Grassino E., Milic-Emili J. Intrinsic PEEP and arterial PC02 in stable patients with chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 1990; 141: 1194-1197.

25. Broseghini C., Brandolese R., Poggi R. et al. Respiratory mechanics during the first day of mechanical ventilation in patients with pulmonary edema and chronic airway obstruction. Am. Rev. Respir. Dis. 1988; 138: 355-361.

26. Similowski T., Muir J.-P., Derenne J.-P. Les bronchopneu-mopathies chroniques obstructives. Paris: John Libbey Eurotext; 1999.

27. Fleury B., Murciano D., Talamo C. et al. Work of breathing in patients with chronic obsructive pulmonary disease in acute respiratory failure. Am. Rev. Respir. Dis. 1985; 131: 822-827.

28. Pepe P.E., Marini J .J. Occult positive end-expiratory pressure in mechanically-ventilated patients with airflow obstruction. Am. Rev. Respir. Dis. 1982; 126: 166-170.

29. Gibson G.J. Pulmonary hyperinflation: a clinical overview. Eur. Respir. J. 1996; 9: 2640-2649.

30. Davy H. Researches, chemical and philosophical, chiefly concerning nitrous oxide, or dephlogisticated nitrous air, and its respiration. London: Johnson; 1800.

31. Clausen J.L., Wanger J.S. For the Workshop participants. Consensus Statement on measurements of lung volumes in humans. ATS/NHLBI Consensus Document 12 Nov 03. Available at http://www.thoracic.org/adobe/lungvolume.pdf

32. Cala S.J., Kenyon C.M., Ferrigno G. et al. Chest wall and lung volume estimation by optical reflectance motion analysis. J. Appl. Physiol. 1996; 81: 2680-2689.

33. Brown R., Enright P., Leith D. Multiple-breath helium dilution measurements of lung volumes in adults. Eur. Respir. J. 1998; 11: 246-255.

34. Stanescu D.C., Rodenstein D., Cauberghs M. et al. Failure of body plethysmography in bronchial asthma. J. Appl. Physiol. 1982; 52: 939-948.

35. Yang S., Kaminski D., Sliwinski P. Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1997; 156: 55-59.

36. Fairshter R.D. Airway hysteresis in normal subjects and individuals with chronic airflow obstruction. J. Appl. Physiol. 1985; 58: 1505-1510.

37. Tantucci C., Duguet A., Similowski T. et al. Effect of salbuta-mol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur. Respir. J. 1998; 12: 799-804.

38. Duranti R., Filippelli M., Bianchi R. et al. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest 2002; 122: 2009-2014.

39. Dolmage T.E., Goldstein R.S. Repeatability of inspiratory capacity during incremental exercise in patients with severe COPD. Chest 2002; 121: 708-714.

40. O'Donnell D.E., Lam M., Webb K.A. Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158: 1557-1565.

41. Pellegrino R., Brusasco V. Lung hyperinflation and flow limitation in chronic airway obstruction. Eur. Respir. J. 1997; 10: 543-549.

42. Pellegrino R., Rodarte J.R., Brusasco V. Assessing the reversibility of airway obstruction. Chest 1998; 114: 1607-1612.

43. Hadcroft J., Calverley P.M.A. Alternative methods for assessing bronchodilatator reversibility in chronic obstructive pulmonary disease. Thorax 2001; 56: 713-720.

44. Murariu C., Ghezzo H., Milic-Emili J., Gautier H. Exercise limitation in obstructive lung disease. Chest 1998; 114: 965-968.

45. Marin J.M., Carrizo S.J., Gascon M. et al. Inspiratory capacity, dynamic hyperinflation, breathlessness and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163: 1395-1399.

46. Di Marco F., Milic-Emili J., Boveri B. et al. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD: Eur. Respir. J. 2003; 21: 86-94.

47. Casanova C., Cote C., de Torres J.P. et at. The inspiratory to total lung capacity ratio predicts mortality in patients with COPD. Am. J. Respir. Crit. Care Med. Articles in Press. Published on December 10, 2004 as doi: 10.1164/rccm.200407-8670C. Available at http://ajrccm.atsjournals.org/cgi/reprint/200407-8670Cvl.

48. Martinez F.J., Montes de Oca M., Whyte R.I. et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation and respiratory muscle function. Am. J. Respir. Crit. Care Med. 1997; 155: 1984-1990.

49. Chrystyn H., Mulley B.A., Peak M.D. Dose response relation to oral theophylline in severe chronic obstructive airways disease. Br. Med. J. 1988; 297: 1506-1510.

50. Celli B., ZuWallack R., Wang S., Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743-1748.

51. O'Donnell D.E., Fluge T., Gerken F. et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23: 832-840.

52. Magnussen H. Exercise limitation in COPD: mechanisms, assessment and treatment. Eur. Respir. Rev. 2004; 14 (89): 35-39.